JNJ9:45 PMJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerjnj.com
JNJ4:27 PMJohnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferencejnj.com
JNJ8:45 AMJohnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective Septemberjnj.com
JNJ8:30 AMJohnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerjnj.com
JNJ5:42 PMJohnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovationjnj.com
JNJ5:28 PMJohnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Resetjnj.com
JNJ8:30 AMTECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomajnj.com
JNJ7:00 AMJohnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical Systemjnj.com
JNJ8:11 AMJohnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Awardjnj.com